Almost sold these shares today for 17.80........decided to hold them for 19 ish.........probably a mistake but I feel the revisions upward are going to put us there in next couple weeks. IMO it is time to buy.....
so far, so good looks like IMGN wants to hold up and test $17 again soon.
After reading the comments about preparing for another DJ CC debacle I sent IMGN a message suggesting they do some prep work prior to the cc to avoid repeating the recent poor performances. Let's see how it goes. They usually do well leading up to the cc and then an analyst asks a somewhat challenging question and they provide a weak, weasely answer that says nothing, then we get more about delay, nothing tangible about progress, lots of promises about the future, they use a word that should be banned "monetization" (it's worse than saying shank to a golfer...sorry). Hopefully, Dan will say I am the new CFO and the BOD is looking for a new CEO, but I doubt it.
From the IV board recently, 289 study has commenced and Roche started another very large 2500-patient Kadcyla + Perjeta study. People may think that Kad sales started off slow, but Roche is making a massive investment in Kad trials, they must think Kad can produce $millions in annual revs based on the trials in which they are investing.